Picture
 

Tom Lawlor Banned Two Years For PED

Written by Tom Ngo
February 25th, 2017
Share on Facebook0Google+0Tweet about this on Twitter

ufc tom lawlor

“Filthy” Tom Lawlor will have two years to try and clean up his act. The USADA has banned the UFC veteran two years following a flunked random drug test.

Lawlor was initially notified of his failed exam stemming from a October 10 out-of-competition screening on November 3. The 33-year-old had been provisionally suspended until further investigation.

The USADA dropped the hammer on Lawlor after it was determined he used Ostarine, which is “a prohibited substance in the category of Anabolic Agents and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the WADA Prohibited List.”

“Ostarine, also known as MK-2866 and Enobosarm, is a non-FDA approved selective androgen receptor modulator (SARM) which is illegally sold in the United States and globally as a performance-enhancing substance,” the USADA expressed in a statement. “Ostarine is not currently available as a prescription medication in any country, and its unauthorized use may carry serious side effects.

“Nonetheless, ostarine has been found as a declared and undeclared ingredient in many dietary supplements sold in the United States, which has prompted the U. S. Food and Drug Administration (FDA) to issue warning letters to specific dietary supplement manufacturers stating that ostarine is an unapproved new drug and that selling the drug is in violation of the Federal Food, Drug, and Cosmetic Act (FDCA).”

If he chooses, Lawlor will be able to resume his MMA career no earlier than October 10, 2018, two years after the date his positive sample was collected.

Lawlor is an average MMA fighter having accumulated a 10-6 (1 NC) record throughout his 10-year professional career. He’s gone just 6-5 since joining the UFC in 2008. If anything, Lawlor is more known for his comedic antics at weigh-ins than his performances inside the cage.

Don’t forget to follow @5thRound on Twitter, Facebook and Google+!



COMMENTS